Free Trial
OTCMKTS:MKKGY

Merck KGaA (MKKGY) Stock Price, News & Analysis

Merck KGaA logo
$28.72 +0.15 (+0.53%)
(As of 12/20/2024 05:55 PM ET)

About Merck KGaA Stock (OTCMKTS:MKKGY)

Key Stats

Today's Range
$28.29
$28.88
50-Day Range
$28.57
$35.74
52-Week Range
$28.29
$39.17
Volume
152,281 shs
Average Volume
128,497 shs
Market Capitalization
$18.56 billion
P/E Ratio
17.73
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Buy

Company Overview

Merck KGaA operates as a science and technology company in Germany. It operates through Life Science, Healthcare, and Electronics segments. The company's Life Science segment offers tools, chemicals, and equipment for academic labs, biotech, and pharmaceutical manufacturers, as well as industrial sector. This segment provides drug manufacturers with process development expertise and technologies, such as continuous bioprocessing; testing kits and services; reagents and services; testing solutions that analyze air, water, and soil; and testing and tools, as well as products that help test nutritional value and identify quality inconsistencies. Its Healthcare segment discovers, develops, manufacturers, and markets prescription drugs and biopharmaceuticals for the treatment of oncology, neurology and immunology, fertility, endocrinology, as well as cardiovascular, diabetes, thyroid disorders, and multiple sclerosis; general medicines; and injection device and disease monitoring software. The Electronics segment supplies materials for the semiconductor and display industries and surface design, such as delivery systems and services, as well as surface solutions, including cosmetics, effect pigments, and functional solutions. In addition, it has in-licensing agreement with Debiopharm International SA for developing and commercializing drug candidates for the treatment of head and neck cancer; Jiangsu Hengrui Pharmaceuticals Co. Ltd. for developing, manufacturing, and commercializing drug candidates for the treatment of metastatic colorectal cancer; and Abbisko Therapeutics Co. Ltd. for developing and commercializing of drug candidates for the treatment of tenosynovial giant cell tumor, as well as license and collaboration agreement with Merck KGaA to discover two targeted protein degraders against critical oncogenic proteins. The company was founded in 1668 and is headquartered in Darmstadt, Germany. Merck KGaA operates as a subsidiary of E. Merck KGaA.

Merck KGaA Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
51st Percentile Overall Score

MKKGY MarketRank™: 

Merck KGaA scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Merck KGaA are expected to grow by 9.63% in the coming year, from $1.87 to $2.05 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Merck KGaA is 17.08, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 113.45.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Merck KGaA is 17.08, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 89.58.

  • Price to Earnings Growth Ratio

    Merck KGaA has a PEG Ratio of 2.32. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Merck KGaA has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Merck KGaA have been sold short.
  • Short Interest Ratio / Days to Cover

    Merck KGaA has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Merck KGaA has recently decreased by 97.19%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Merck KGaA does not currently pay a dividend.

  • Dividend Growth

    Merck KGaA does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.00% of the outstanding shares of Merck KGaA have been sold short.
  • Short Interest Ratio / Days to Cover

    Merck KGaA has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Merck KGaA has recently decreased by 97.19%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Merck KGaA has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 7 news articles for Merck KGaA this week, compared to 4 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Merck KGaA insiders have not sold or bought any company stock.

  • Percentage Held by Institutions

    Only 0.10% of the stock of Merck KGaA is held by institutions.

  • Read more about Merck KGaA's insider trading history.
Receive MKKGY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merck KGaA and its competitors with MarketBeat's FREE daily newsletter.

MKKGY Stock News Headlines

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share
The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.
DZ BANK AG Sticks to Its Buy Rating for Merck KGaA (0O14)
See More Headlines

MKKGY Stock Analysis - Frequently Asked Questions

Merck KGaA's stock was trading at $31.93 at the beginning of 2024. Since then, MKKGY stock has decreased by 10.1% and is now trading at $28.72.
View the best growth stocks for 2024 here
.

Shares of MKKGY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

Today
12/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:MKKGY
Previous Symbol
OTCMKTS:MKKGY
CIK
N/A
Employees
62,908
Year Founded
N/A

Profitability

Net Income
$3.06 billion
Pretax Margin
16.09%

Debt

Sales & Book Value

Annual Sales
$22.72 billion
Cash Flow
$9.94 per share
Book Value
$42.40 per share

Miscellaneous

Free Float
N/A
Market Cap
$18.56 billion
Optionable
Not Optionable
Beta
0.93
20 High-Yield Dividend Stocks that Could Ruin Your Retirement Cover

Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.

Get This Free Report

This page (OTCMKTS:MKKGY) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners